Abstract
THE gag and pol genes of the human immunodeficiency virus type 1 (HIV-1) (ref. 1) are translated as two polyproteins, Pr55gag and Prl60gag-pol(refs 2-6), which are subsequently cleaved by the action of a virus-encoded protease into the four structural gag proteins of the virion core (pi7, p24, p7 and p6)7–9and the pol-encoded enzymes essential for retrovirus replication (protease, reverse transcriptase, ribonuclease H, and endonuclease). Mutational inactivation of the proteases of HIV-110–13 and other retro viruses14,15results in immature, non-infectious virions, indicating that exogenous inhibition of the protease may represent an attractive approach to anti-AIDS therapy. Here we demonstrate that synthetic peptide analogues, which are potent inhibitors of purified HIV-1 protease, inhibit the processing of the viral polyproteins in cultures of HIV-1-infected T lymphocytes and attenuate viral infectivity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gallo, R. C. & Montagnier, L. Scient. Am. 259, 40–48 (1988).
Ratner, L. et al. Nature 313, 277–284 (1985).
Sanchez-Pescador, R. et al. Science 227, 484–492 (1985).
Wain-Hobson, S. et al. Cell 40, 9–17 (1985).
Muesing, M. A. et al. Nature 313, 450–458 (1985).
Jacks, T. et al. Nature 331, 280–283 (1988).
Veronese, F. D. et al. AIDS Res. human Retrovir. 3, 253–262 (1987).
Veronese, F. D. et al. J. Virol. 62, 795–801 (1988).
Henderson, L. E., Copeland, T. D., Sowder, R. C., Schultz, A. M. & Oroszlan, S. in Human Retroviruses, Cancer, and AIDS: Approaches to Prevention and Therapy 135–147 (Alan R. Liss, New York, 1987).
Kohl, N. E. et al. Proc. natn. Acad. Sci., U.S.A. 85, 4686–4690 (1988).
Peng, C., Ho, B., Chang, T. & Chang, N. J. Virol. 63, 2550–2556 (1989).
Gottlinger, H., Sodroski, J. & Haseltine, W. Proc. nat. Acad. Sci. U.S.A. 86, 5781–5785 (1989).
Seelmecer, S., Schmidt, H., Turk, V. & von der Helm, K. Proc. natn. Acad. Sci., U.S.A. 85, 6612–6616 (1988).
Crawford, S. & Goff, S. J. Virol. 53, 899–907 (1985).
Katoh, I. et al. Virology 145, 280–292 (1985).
Debouck, C. et al. Proc. natn. Acad. Sci, U.S.A. 84, 8903–8906 (1987).
Meek, T. D. et al. Proc. natn. Acad. Sci, U.S.A. 86, 1841–1845 (1989).
Pearl, L. H. & Taylor, W. R. Nature 329, 351–354 (1987).
Navia, M. A. et al. Nature 337, 615–620 (1989).
Wlodawer, A. et al. Science 245, 616–621 (1989).
Holladay, M. W., Salituro, F. G. & Rich, D. H. J. med. Chem. 30, 374–383 (1987).
Szelke, M., Jones, D., Atrash, B., Hallett, A. & Leckie, B. in Peptioes Structure and Function. Proceedings of Eighth American Peptide Symposium (eds Hruby, V. J. & Rich, D. H.) 579–582 (Pierce Chemical Co., Rockford, Illinois, 1983).
Dreyer, G. B. et al. Proc. natn. Acad. Sci. U.S.A. (in the press).
Moore, M. L. et al. Biochem. Biophys. Res. Comm. 159, 420–425 (1989).
Darke, P. L. et al. Biochem. Biophys. Res. Comm. 156, 297–303 (1988).
Matthews, T. J. et al. Proc. Acad. natn. Sci., U.S.A. 84, 5424–5428 (1987).
Mervis, R. J. et al. J. Virol. 62, 3993–4002 (1988).
Popovic, M., Sarngadharan, M., Read, E. & Gallo, R. Science 224, 497–500 (1984).
Laemmli, U. K. Nature 227, 680–685 (1970).
Lambert, D. M. & Pons, M. W. Virology 130, 204–214 (1983).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meek, T., Lambert, D., Dreyer, G. et al. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature 343, 90–92 (1990). https://doi.org/10.1038/343090a0
Issue Date:
DOI: https://doi.org/10.1038/343090a0
This article is cited by
-
Artificial neural network method for predicting HIV protease cleavage sites in protein
Journal of Protein Chemistry (1998)
-
Progress in the discovery of orally bioavailable inhibitors of HIV protease
Perspectives in Drug Discovery and Design (1995)
-
Current Status of the Development of HIV Protease Inhibitors and Their Clinical Potential
Clinical Immunotherapeutics (1995)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.